Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Theralase Technologies Inc (OP:TLTFF)

0.1350 -0.0028 (-2.03%)
Streaming Delayed Price Updated: 2:46 PM EDT, Jun 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Theralase Technologies Inc

< Previous 1 2 3 Next >
Theralase Completes Annual General and Special Meeting
Toronto, Ontario--(Newsfile Corp. - June 12, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical... 
Via Newsfile
Theralase Annual General Meeting
Toronto, Ontario--(Newsfile Corp. - June 5, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a... 
Via Newsfile
Theralase(R) 1Q2025 Financial Statements
Toronto, Ontario--(Newsfile Corp. - May 30, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a... 
Via Newsfile
CORRECTION FROM SOURCE: Theralase to Present Groundbreaking Research at ASTRO 2025
This Press Release removes references to preclinical data that has not yet been presented.Toronto, Ontario--(Newsfile Corp. - May 29, 2025)... 
Via Newsfile
CORRECTING AND REPLACING: Theralase(R) Demonstrates Effective Treatment of Herpes
Via ACCESS Newswire
Theralase(R) Launches New Clinical Study Site in Canada
Via ACCESSWIRE
Theralase to Present Groundbreaking Research at ASTRO 2025
Toronto, Ontario--(Newsfile Corp. - May 28, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a... 
Via Newsfile
Theralase Provides Corporate Update
Toronto, Ontario--(Newsfile Corp. - May 20, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a... 
Via Newsfile
Theralase Clinical Data Presented at Canadian Bladder Cancer Forum and American Urological Association
Toronto, Ontario--(Newsfile Corp. - May 5, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a... 
Via Newsfile
Theralase Discovers New Mechanism of Action of Lead Drug
Toronto, Ontario--(Newsfile Corp. - April 28, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a... 
Via Newsfile
Theralase(R) Closes Non-Brokered Private Placement
Toronto, Ontario--(Newsfile Corp. - April 14, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a... 
Via Newsfile
Ruvidar More Effective in the Treatment of Herpes than FDA-Approved Treatments
Toronto, Ontario--(Newsfile Corp. - April 10, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical... 
Via Newsfile
Ruvidar Demonstrates 7 Year Complete Response
Toronto, Ontario--(Newsfile Corp. - April 7, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical... 
Via Newsfile
Ruvidar Effective in the Treatment of Herpes
Toronto, Ontario--(Newsfile Corp. - March 24, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a... 
Via Newsfile
Theralase(R) Releases 2024 Annual Financial Statements
Toronto, Ontario--(Newsfile Corp. - March 12, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a... 
Via Newsfile
Theralase(R) Closes Non-Brokered Private Placement
Toronto, Ontario--(Newsfile Corp. - March 11, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a... 
Via Newsfile
Theralase(R) Therapy Improves Motor and Non-Motor Function in Parkinson's Patients
Toronto, Ontario--(Newsfile Corp. - March 10, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a... 
Via Newsfile
Theralase(R) Demonstrates Efficacy of Rutherrin(R) in Destruction of Non-Hodgkin's Lymphoma
Toronto, Ontario--(Newsfile Corp. - February 25, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical... 
Via Newsfile
Topics Death
Exposures Death
Theralase(R) Demonstrates Effective Treatment of Herpes
Via ACCESS Newswire
Theralase(R) Releases Latest Research on Inactivation of Herpes Simplex Viruses
Via ACCESS Newswire
Theralase(R) Interim Clinical Data to be Presented at the 2025 AUA Annual Meeting
Via ACCESS Newswire
Theralase(R) Launches Three New Clinical Study Sites in USA
Via ACCESSWIRE
Theralase(R) Release’s 3Q2024 Financial Statements
Via ACCESSWIRE
Theralase(R) Closes Non-Brokered Private Placement
Via ACCESSWIRE
Theralase(R) Extends Warrants
Via ACCESSWIRE
Theralase(R) Provides Update on Bladder Cancer Clinical Study
Via ACCESSWIRE
Theralase(R) Closes Non-Brokered Private Placement and Issues Stock Options
Via ACCESSWIRE
Theralase(R) Extends Warrants
Via ACCESSWIRE
Ruvidar(TM) Proven More Effective Than Acyclovir in Destruction of Herpes Simplex Virus
Via ACCESSWIRE
Rutherrin(R) Increases Efficacy of Chemotherapy for Lung Cancer
Via ACCESSWIRE
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.